On November 3, Axsome Therapeutics rose 5.42% in Regular Trading, trading at $144.34/share, with turnover of $20.9998 million.
The move followed stronger-than-expected third-quarter results and a subsequent maintained outperform rating from a major bank, even as its price target was trimmed to $273 from $295.
Axsome Therapeutics reported a third-quarter adjusted loss of $0.25 per share, better than consensus expectations of about $0.56 to $0.68, while revenue reached $259.7 million, above forecasts near $249 million to $250 million and up about 52% year over year. Net loss narrowed to about $12.9 million from $47.2 million a year earlier, reflecting continued commercial momentum led by Auvelity. Additional recent company developments include a settlement resolving SUNOSI patent litigation and an AXS-12 narcolepsy decision date set for May 1, 2027.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments